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An increasing number of patients are being referred to pancreatic centres around
the world due to often incidentally discovered cystic neoplasms of the pancreas.
The evaluation and management of pancreatic cystic neoplasms is a controversial
topic and with existing guidelines based on a lack of strong evidence there is
discordance between centres and guidelines with regard to when to offer surgery
and when to favour surveillance. The frequency, duration and modality of
surveillance is also controversial as this is resource-consuming and must be
balanced against the perceived benefits and risks involved. While there is
consensus that the risk of malignancy should be balanced against the life-
expectancy and comorbidities, the indications for surgery and surveillance
strategies vary among the guidelines. Thus, the tug of war between surveillance
or resection continues. Here we discuss the recommendations from guidelines
with further accumulating data and emerging reports on intraductal papillary
mucinous neoplasm in the literature.
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Core tip: For patients with intraductal papillary mucinous neoplasia detected in the
pancreas, there is currently debate over the frequency, duration and modality of
surveillance in the long-term. Surveillance is resource-consuming and must be balanced
against the likely benefits and perceived risks for malignant transformation. Furthermore,
the risk of malignancy should be balanced against the overall life-expectancy and
comorbidities. Notably, the indications for either surgery or surveillance vary among the
available guidelines. Thus, the tug of war between surveillance or resection continues.
The recommendations from existing guidelines are highlighted with further
accumulating data and emerging reports from the intraductal papillary mucinous
neoplasm literature.
Citation: Aunan JR, Jamieson NB, Søreide K. Observation or resection of pancreatic





An increasing number of patients are being referred to pancreatic centres around the
world due to often incidentally discovered cystic neoplasms of the pancreas. High
quality radiological imaging is increasingly utilised and although pancreatic cystic
neoplasms have most likely always existed, it is only more recently that guidelines for
follow-up, diagnosis and management have been issued. These guidelines themselves
are based on the scarce data available.  Intraductal  papillary mucinous neoplasm
(IPMN)  was  first  described  in  1982  by  Ohashi  and  was,  until  the  turn  of  the
millennium,  considered  a  rare  entity  but  is  now  among  the  most  commonly
discovered and surgically resected pancreatic cystic lesions[2].
The evaluation and management of pancreatic cystic neoplasms is a controversial
topic, and the existing guidelines are based on a lack of strong evidence. Thus, there is
discordance between practice among centres and the available guidelines with regard
to when and to whom surgery should be offered and when to favour surveillance. The
frequency, duration and modality of surveillance is also controversial, as this strategy
is resource-consuming and must be balanced against the perceived benefits and risks
involved.
The first guidelines came after the turn of the millennium, with four guidelines
now in place (Table 1), including the International Association of Pancreatology (IAP,
also called “Fukuoka”) guidelines, European Study Group on Cystic Tumors of the
Pancreas[4], American Gastroenterological Association (AGA) and American College
of Gastroenterology (ACG) clinical guideline[6]. While there is consensus that the risk
of malignancy should be balanced against life-expectancy and comorbidities,  the
indications for surgery and surveillance strategies vary among the guidelines. Thus,
the tug of war between surveillance or resection continues (Figure 1). Here we discuss
the recommendations from guidelines with further accumulating data and emerging
reports on IPMN in the literature.
IPMN IS A PREMALIGNANT CONDITION
IPMN harbours a malignant potential and is considered a premalignant condition of
the  pancreas.  The underlying mechanisms of  cancer  progression and malignant
evolution is poorly understood, but knowledge is emerging in this field[8-10]. Thus, the
main rationale  for  surgery is  to  resect  lesions that  either  harbour early  invasive
cancerous lesions or preferably to remove lesions that contain high-grade dysplasia
but have yet to progress into invasive cancer. Based on recent data, approximately one
in every four resected IPMN have histologically confirmed malignancy[11].
POPULATION AT RISK FOR IPMN
The exact incidence of IPMN is not known, but it is estimated to be present in 2%-45%
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Table 1  Comparison of existing guidelines for intraductal papillary mucinous neoplasia of the pancreas
Guideline (yr) IAP (2017) European (2018) AGA (2015) ACG (2018)




team. Refer if ≥ 1 high risk
characteristics
≥ 1 worrisome feature and ≥ 1
of: definitive mural nodule ≥
5 mm, MPD involvement,
suspicious or positive
cytology.
≥ 1 relative indication
without significant co-
morbidities
Consider surgery in young fit
patients with cysts > 2 cm
≥ 2 relative indications with
significant co-morbidities





High risk stigmata: Jaundice;
Enhancing mural nodule > 5
mm; MPD > 10 mm
Absolute criteria: Jaundice;
Enhancing mural nodule ≥ 5
mm; MPD ≥ 10 mm; Solid
mass; Positive cytology
High risk features: Cyst size ≥




component; MPD > 5 mm;
Abrupt pancreatic duct
calibre change with distal
atrophy; Cyst size ≥ 3 mm;
Cyst growth 3 mm/yr;
Positive cytology; Pancreatitis




cyst; Cyst size ≥ 3 cm;
Enhancing mural nodule < 5
mm; Enhancing thickened
cyst wall; MPD 5-9 mm;
Abrupt pancreatic duct
calibre change with distal
atrophy; Growth ≥ 5 mm/2
yr; Elevated serum Ca19-9
Relative indications:
Pancreatitis secondary to
cyst; Cyst diameter ≥ 40 mm;
Enhancing mural nodule < 5
mm; MPD 5-9 mm; Growth
rate > 5 mm/yr; New onset
diabetes mellitus; Elevated
serum Ca19-9
Surveillance intervals < 1 cm: 6 mo, then every 2 yr;
1-2 cm: 6 mo 1st yr, yearly for
2 yr, then every 2 yr; 2-3 cm:
3-6 mo 1st yr, then yearly; > 3
cm 3-6 mo
6 mo 1st yr, then yearly 1, 3 and 5 yr < 1 cm: Every 2 yr; 1-2 cm:
Every 1 yr; 2-3 cm: Every 6-12
mo; > 3 cm Every 6 mo and
consider referral to MDT
Surveillance modality < 2 cm MRI or CT; 2 cm MRI
and EUS
MRI and/or EUS Serum
Ca19-9
MRI MRI and/or EUS
IAP: International Association of Pancreatology; AGA: American Gastroenterology Association; ACG: American College of Gastroenterology; MPD: Main
pancreatic duct; MRI, Magnetic resonance imaging; EUS: Endoscopic ultrasound; FNA: Fine needle aspiration; IPMN: Intraductal papillary mucinous
neoplasm; CT: Computed tomography; MDT: Multidisciplinary team; MD: Main duct; MT: Mixed type.
of the general population[4]. Notably, many IPMNs are incidentally discovered during
cross-sectional  imaging  performed  for  other  unrelated  medical  reasons.  This
particularly holds true for the aging population when the prevalence of numerous
other medical conditions increase[12], which leads to an increasing number of cross-
sectional  imaging  being  undertaken  for  work-up  or  surveillance.  Thus,  for
transabdominal  scans  involving  the  pancreas,  this  often  leads  to  the  incidental
detection  of  cystic  lesions  in  the  pancreas  with  a  request  for  review  by
pancreatologists and surgeons. The influence of ageing on loss of functional reserve
follows many of the same mechanisms that also lead to risk of premalignant and
malignant  disease.  Thus,  finding incidental  IPMNs is  likely to increase with the
widespread use of cross-sectional imaging. Resection vs  surveillance needs to be
tailored to the likely clinical impact and outcome for the particular lesion and person.
For  one,  extended  surveillance  needs  to  take  into  account  the  life-time  risk  of
malignant development. Furthermore, when considering a need for resection, the type
of  surgery  needs  to  be  taken  into  account  together  with  patient  comorbidities.
Notably, the risk profile, including mortality and morbidity is considerably different
in  pancreatoduodenectomy  (mortality  3%-4%)  compared  to  a  distal  resection
(mortality < 1.5%)[14,15]. Furthermore, enucleations and central resections have their
own morbidity  profile.  Lastly,  a  total  pancreatectomy (sometimes  indicated  for
disease affecting the entire gland) needs to be considered carefully as the risk, benefit
and long-term consequences are considerable.
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Figure 1
Figure 1  Tug of war between resection and observation in intraductal papillary mucinous neoplasm. Depicted
for illustration is the tug of war between strategies for intraductal papillary mucinous neoplasm, either resection or
observation. Decision making is based on available data, which currently are conflicting. Reaction on first-event
cross-sectional imaging (the Picture) may prevent information obtained from serial, temporal evaluation (the Movie) of
how intraductal papillary mucinous neoplasm lesions may change in character, size and context.
CONSIDERING PATIENT FITNESS
An important factor in limiting overtreatment and morbidity from surgery is careful
patient  selection  by  limiting  surgery  in  highly  comorbid  surgical  candidates.
Progression  to  cancer,  even  in  the  presence  of  worrisome features,  may  be  less
common than previously thought, according to recent observational studies. In one
observational group of IPMNs with worrisome features, the 5 year disease specific
survival was 96% suggesting that conservative management was appropriate, but
high-risk stigmata is associated with a 40% risk of IPMN-related death suggesting
surgery as the treatment of choice in fit patients[18]. In a meta-analysis on patients unfit
for surgery but with worrisome features and high risk stigmata, the IPMN related
mortality was low, especially for branched duct IPMN[19], and death from other causes
was  much  more  common.  In  another  observational  study  of  low  risk  lesions,
malignancy occurred rarely (4.2%), but the development of main pancreatic duct
dilatation was strongly associated with malignant transformation[20].
RESECTION OR SURVEILLANCE–THE DILEMMA
Surgery is  offered to a  subset  of  patients  with IPMN, yet  pancreatic  resection is
associated with significant morbidity and even mortality. Thus, it is important to
establish a better understanding of the impact of worrisome features so that surgery is
offered when justified. The decision to resect an IPMN lesion is often based on any
one of the mentioned guidelines, yet all current consensus guidelines are generated
from low quality data. Also, even if based on low quality data, the recommendations
vary  considerably  (Table  1).  Furthermore,  the  indications  may be  “absolute”  or
“relative” (Table 1)  with partial  disagreement between guidelines and hence the
ongoing debate among pancreatologists and pancreatic surgeons.
Both the European guidelines and the IAP guidelines justify resection if one or
more is present: (A) Jaundice due to the IPMN; (B) Enhancing mural nodule over 5
mm; or (C) Main pancreatic duct dilatation over 10 mm (Table 1). These criteria are
referred to as absolute indications in the European guidelines and high-risk stigmata
in the IAP guidelines (Table 1). The European guidelines also opt for surgery if one or
more of several relative indications are present in healthy individuals, which includes
pancreatitis,  cyst diameter over 40 mm, growth rate over 5 mm/year,  new onset
diabetes mellitus and elevated Ca19-9 among others.  The IAP guidelines refer to
many of the same criteria as worrisome features and also recommend surgery but
only  with  some  additional  basic  criteria  present,  namely  main  pancreatic  duct
involvement, mural nodule or positive/suspicious cytology. While the European and
IAP guidelines are similar with regards to surgical indications, differences (such as
cyst size) are present (Table 1). The European guidelines recommend surgery when
cyst size is over 40 mm whereas the IAP guidelines opt for surgery if cyst size is over
20 mm in young fit individuals.
The AGA guidelines for surgical resection require both a solid component AND a
dilated pancreatic duct OR a positive cytology on endoscopic ultrasound with fine-
needle aspiration. AGA does not mention degree of dilatation of the main pancreatic
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duct.
The ACG guidelines fail to provide clear guidance on when to offer surgery but
recommend referral to multidisciplinary teams if high risk characteristics are present.
This provides opportunity for personalisation of treatment selection according to the
teams and their members. For worrisome risk features, models have been proposed to
predict risk of malignancy or high-grade dysplasia, with modest prediction values
achieved[21].
In a retrospective study evaluating accuracy of resection criteria in patients with
pancreatic cysts,  the cohort included 75 patients with IPMN[22].  The investigators
compared the final pathologic outcome of surgically removed pancreatic cysts with
the recommended indications for resection according to three different guidelines
(IAP, the European and AGA guidelines). For patients with suspected IPMN (n = 75),
resection was justified in 36% of 67% (54%), 36% of 68% (53%) and 32% of 54% (59%)
of patients based on the recommendations for surgery in the IAP, European and AGA
guidelines, respectively[22]. The AGA guideline would have avoided resection in 21%
of 75% (28%) patients, the IAP in 8% of 75% (11%) and the European in 7% of 75%
(9%) if the guidelines would have been applied strictly. However, 4% of 33% patients
(12%) with high-grade dysplasia or malignancy would have been missed with the
AGA guidelines, compared with none if following the IAP or European guidelines[22].
This  demonstrates  that  all  guidelines  will  currently  result  in  a  degree  of
overtreatment, imposing a potential risk to the patient. The AGA guidelines, which
represent the more conservative approach towards resection for IPMNs (Table 1),
would have missed the surgical indication for two patients with malignancy and two
patients  with  high-grade  dysplasia[22].  This  indicates  that,  based  on  the  current
guidelines, a degree of overtreatment is necessary in order to capture all malignant
and high-grade dysplastic lesions.
IPMNS OF MAIN DUCT, BRANCH DUCT AND MIXED TYPE
Dilatation of the main duct is considered to be a strong risk feature for malignancy,
yet controversy persists regarding optimal duct diameter cut-off for resection and the
need for  either  observation or  resection in main duct  IPMNs[23,24].  The European
guidelines recommend resection in all fit individuals, the IAP guidelines require the
presence  of  any  high-risk  stigmata,  the  ACG  recommends  referral  to  a
multidisciplinary team discussion whereas the AGA guidelines do not mention this
group with main duct dilatation specifically. A recent study demonstrated a high risk
for malignancy with main duct dilatation[23], while another study from Verona did not
call main duct dilatation as a risk for malignancy for patients undergoing surveillance.
Notably, the bi-institutional series[23] from Johns Hopkins and Karolinska was based
on  resected  IPMNs,  thus  potentially  biasing  the  results  towards  patients  who
underwent  resection[23]  rather  than  all  patients  diagnosed  with  a  dilated  main
pancreatic duct. However, the Johns Hopkins/Karolinska series found an increased
risk of malignancy even in the middle-ranged size of dilated main ducts (5-9 mm). In
contrast, the Verona study included both resection and surveillance patients and did
not find main duct dilatation alone to be a significant risk factor for malignancy,
although it increased risk together with other worrisome features. Thus, we believe
the jury is still out on the true risk associated with main duct dilatation in IPMN.
Branch duct IPMN are presumed to have a very low risk of malignancy, yet the risk
is definite[20].  Controversy persists regarding criteria for continued observation or
resection for these lesions, although the updated international guidelines aim to have
better precision in predicting malignancy risk[25].  Initial cysts size (> 40 mm) and
annual growth rate may be indicators for risk of malignancy in branch duct lesions
observed over time[26]. A French study suggested that branch duct IPMN in men with
recent  onset  diabetes  should  be  considered  for  resection,  as  the  incidence  of
malignancy and high-grade dysplasia was higher in this group[27]. This is in line with
the evolving evidence that developing fasting blood glucose intolerance is associated
with risk of pancreatic malignancy[28,29]. New onset diabetes associated with an IPMN
is also a clear indication for resection in healthy individuals when following the
European guidelines as it is a “relative indication” that should lead to resection in
patients without comorbidities (Table 1). New onset diabetes is not a criterium for
resection  in  the  other  guidelines,  but  the  ACG  guidelines  acknowledges  its
importance and recommend further investigation and tighter surveillance.
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INFORMED DECISION-MAKING: A STEPWISE APPROACH
The first step in the decision between surgery or surveillance of a pancreatic cystic
lesion is making the correct diagnosis, which is not always straight forward in itself.
In  addition to  evaluating the patient’s  overall  condition and fitness  for  surgery,
information from a variety of modalities can be assimilated in order to enhance the
decision-making process.
Transsectional  body  imaging  by  magnetic  resonance  imaging  and  computed
tomography
Magnetic  resonance  imaging  is  usually  the  radiologic  modality  of  choice  for
classification of IPMN. In the study by Lekkerkerker et al[22], preoperative diagnosis
was correct in 80% of branch duct IPMNs and 89% of the main/mixed type IPMNs. In
other high volume centres the preoperative diagnosis was incorrect in one third of the
cases[30,31], and 20% of presumed branch duct IPMN had main duct involvement at
postoperative histology. Among the conflicting and debated topics is the decision
based on a cross-sectional image. Should one react on the “picture” or the “movie”
(Figure 1)? While some argue that worrisome features present at first presentation
would warrant resection, others uphold the view of further imaging to get a sense of
the “movie” by depicting cystic progression (or stability) over time and thus make a
decision  to  proceed  with  resection  based  on  this  time-dependent  information.
Obviously, the argument against such an approach is the risk of surveilling patients
only  to  discover  a  lesion  that  has  progressed  to  invasive  (or  even  metastatic)
carcinoma. Reports on progression to invasive cancer in some apparently innocuous
lesions followed for many years is what concerns most pancreatic surgeons[32]. In one
series, branch duct cysts that remained ≤ 1.5 cm after 5 years of follow up had a very
low risk of progression to cancer[33]. However, in the population with cyst size > 1.5
cm, a reported 7.5% developed malignancy, thus suggesting these should be followed
beyond 5 years of surveillance.
Endoscopic ultrasound
Contrast-enhanced  endoscopic  ultrasound  has  shown  promising  results  with
improved evaluation of mural nodules in cysts and subsequently the differentiation
between malignant and non-malignant cysts[34]. Using the same contrast-enhanced
endoscopic ultrasound with time intensity curves, blood flow and microvasculature
density  in  IPMN  cysts  can  be  evaluated  and  this  correlates  with  high-grade
dysplasia/malignancy  and  has  potential  to  differentiate  them  from  low-grade
dysplasia[35].
Tumour markers
Serum Ca19-9 and CEA are well-established tumour biomarkers that can help in
decision making in some cases. Significantly elevated levels of these biomarkers in
patients with worrisome lesions (without jaundice) would be suggestive of a higher
risk of invasive cancer[36]. However, the overall sensitivity and specificity remains
poor[37],  and low values do not  infer  a  benign condition.  Thus,  other biomarkers
sampled from cyst fluid or other sources are emerging and of interest.  Particular
interest is expressed in next generation sequencing of pancreatic cystic fluid[38-41].
Investigators  have  reported  KRAS/GNAS  mutations  to  be  present  in  100%  of
IPMNs[39]  and to be highly sensitive and specific (89% and 100%, respectively) for
IPMNs  and  mucinous  cystic  lesions [ 3 9 ] .  Furthermore,  the  addition  of
TP53/PIK3CA/PTEN evaluation provided an 88% sensitivity and 97% specificity for
IPMNs with advanced neoplasia[39]. Further, evaluation of pancreatic juice mutation
concentration by next generation sequencing may help distinguish high-grade from
low-grade  lesions,  and  mutant  TP53/SMAD4  concentrations  could  distinguish
patients  with  malignancy  (e.g.,  invasive  cancer  or  high-grade  dysplasia)  with  a
sensitivity and specificity of about 61% and 96%, respectively[42,43]. However, further
validation is  needed before these methods become integrated within the clinical
setting.
In a large meta-analysis,  a combination of cytology and immunohistochemical
analysis of MUC1 and MUC2 in pancreatic juice samples identified malignant IPMNs
with an area under the curve of 0.85 and sensitivity at 85% and specificity at 65%. In a
test  model,  inclusion  of  cytologic  analysis  of  pancreatic  juice  in  the  guideline
algorithm significantly increased the specificity of detection of malignant IPMNs[44].
More  advanced techniques  including targeted mass  spectrometry  of  peptides
mucin-5AC,  mucin  2  and  prostate  stem  cell  antigen  could  identify  high-grade
dysplasia/cancer with an accuracy of 96%. Thus, there are several ongoing studies
and potential future tools for improved diagnostics and with potential to enhance
surveillance algorithms in the future.
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FUTURE PERSPECTIVES IN THE TUG OF WAR BETWEEN
RESECTION AND OBSERVATION
The future strategy for IPMN treatment should be first and foremost to enhance the
evidence that forms the basis of clinical guidelines currently used to guide cystic
neoplasm management. Large-scale prospective registries of individuals undergoing
cyst surveillance such as the PACYFIC-registry are required to accumulate unbiased
data that will ultimately inform evidence-based guidelines. Furthermore, we must
improve our understanding of the evolutionary biology underlying pancreatic cystic
neoplasms, including IPMNs[9,46]. Improved understanding of the underlying biology
will  enhance our understanding of  risk of  malignant transformation beyond the
stratification provided by traditional anatomical and radiological subsets of main duct
and side branch IPMNs. In addition to the development of molecular assessment of
biopsy specimens, the future role of non-invasive assessment techniques, including
liquid biopsy and enhanced magnetic resonance imaging may be required in order to
detect  high-risk  lesions  early  and  simultaneously  reduce  the  costs  for  life-time
surveillance  strategies.  Alas,  until  this  has  been  achieved  the  tug  of  war  in
management of IPMN lesions will continue.
CONCLUSION
IPMN of the pancreas is increasingly detected in the population, often as an incidental
finding. Several guidelines have been proposed to provide criteria for observation or
resection. The debate continues as to how to identify the most appropriate surgical
candidate. Hence, the tug of war between surveillance and surgery continues until
better evidence for decision making has been achieved.
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